Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
about
Relevance of tumor-infiltrating lymphocytes in breast cancerAptamers: A New Technological Platform in Cancer ImmunotherapySuccessful chemoimmunotherapy against hepatocellular cancer in a novel murine model.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade.Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.Exceptional antineoplastic activity of a dendritic-cell-targeted vaccine loaded with a Listeria peptide proposed against metastatic melanoma.Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Immunotherapy in hepatocellular carcinoma: Primed to make a difference?Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future.Tumor regulation of the tissue environment in the liver.Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.PD-1 Checkpoint Blockade in Combination with an mTOR Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1.Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer.Routing cancer immunology and immunotherapy from the lab to the clinic 4-5 th March 2014, Center for Applied Medical Research and University Clinic, Pamplona, Spain.Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer.Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells.Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.Immunotherapy of hepatocellular carcinomaPotentiating cancer vaccine efficacy in liver cancer
P2860
Q26795598-A2C4063D-CC54-42B7-B077-A9A3F74C1749Q28068981-7385ABF0-109E-4E53-A2F6-50275FFD49CDQ30276134-3581C09F-5A4C-4510-8B85-3D84702590D5Q34515007-2A256485-7959-4E47-8E38-9498957A24B5Q35107009-B5A7BBA8-AA3B-499E-964E-01ADA7FB1F6BQ35764479-4F023F15-A01A-41DA-9CA8-3A230D711E6CQ35922726-F519FAC9-0F06-40D2-889D-489299B246DFQ36413093-489AD6B2-DD4B-4ED6-8958-BFC475845647Q37086138-16117216-A9C0-49C3-8947-74A8D1C7E697Q38349665-5ADF4172-C8CD-445B-9820-B40A856A5561Q38374889-8AB4D5C0-7824-4E4A-B960-FEACDAD39AFAQ38625948-D48D6416-6E71-46EE-99E5-104176CE8529Q38670099-2B5E7495-D8F4-4345-8782-5F1B2E072D43Q38698632-29B81505-F260-4161-B057-9D361455C477Q38749141-A43DC489-D46E-49E6-B0B6-6433CB9CF3E1Q38765760-43E81E48-92A7-41F8-93F5-50E924FE89B5Q39123136-1A659D51-B7A1-4A27-ABFB-953661C80916Q39389346-4DAA212C-776E-4E1F-AB70-3621E58D52F6Q40124899-B3E43AD7-3EA2-4769-B4BC-7F60F66F265AQ42375254-D9C4B207-DD64-4AE1-B2B2-FCDD1A3FFC80Q42729761-7ECEB314-0AD9-4A90-9C5D-CA59EB03DC8DQ42751492-4660027C-087A-4EF0-A488-7F4B44680621Q45070547-995367BC-FC80-4FF6-8F67-DD1E59CF3BEFQ46094829-E87EBF97-AAFA-4707-A31D-B40555DF875EQ46776234-3941D163-6478-4572-9ABC-E27476EF844EQ47301132-8607B535-85AB-48B9-BDBF-F6FCF5188EE2Q48091555-461F4234-FC1D-4616-83A2-9346B5736F6AQ51738252-83E81296-63B5-4F3D-8D9D-8C7534B53048Q54234543-4938447E-FAE3-4F21-A536-65ECD1B01878Q56896669-161BE4B5-6F99-4F9C-A5AD-24E8CF2EF183Q57138867-0F75D089-0CB6-4E87-B0E3-261EB815D4DB
P2860
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Combined immunostimulatory mon ...... ellular carcinoma mouse model.
@en
Combined immunostimulatory mon ...... ellular carcinoma mouse model.
@nl
type
label
Combined immunostimulatory mon ...... ellular carcinoma mouse model.
@en
Combined immunostimulatory mon ...... ellular carcinoma mouse model.
@nl
prefLabel
Combined immunostimulatory mon ...... ellular carcinoma mouse model.
@en
Combined immunostimulatory mon ...... ellular carcinoma mouse model.
@nl
P2093
P50
P1476
Combined immunostimulatory mon ...... cellular carcinoma mouse model
@en
P2093
Aizea Morales-Kastresana
Ana Rouzaut
Arantza Azpilikueta
Ignacio Melero
Ines Gütgemann
Inmaculada Rodriguez
Ivan Martinez-Forero
Maria Jure-Kunkel
Miguel F Sanmamed
Sara Labiano
P304
P356
10.1158/1078-0432.CCR-13-1189
P407
P577
2013-09-12T00:00:00Z